vs
Pacira BioSciences, Inc.（PCRX）与null（SWIM）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是null的1.8倍（$177.4M vs $100.0M），Pacira BioSciences, Inc.净利率更高（1.6% vs -7.0%，领先8.7%），null同比增速更快（14.5% vs 5.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -4.9%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
PCRX vs SWIM — 直观对比
营收规模更大
PCRX
是对方的1.8倍
$100.0M
营收增速更快
SWIM
高出9.5%
5.0%
净利率更高
PCRX
高出8.7%
-7.0%
两年增速更快
PCRX
近两年复合增速
-4.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $100.0M |
| 净利润 | $2.9M | $-7.0M |
| 毛利率 | — | 28.0% |
| 营业利润率 | 3.9% | -10.7% |
| 净利率 | 1.6% | -7.0% |
| 营收同比 | 5.0% | 14.5% |
| 净利润同比 | — | 76.0% |
| 每股收益（稀释后） | $0.07 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXSWIM
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $100.0M | ||
| Q3 25 | $179.5M | $161.9M | ||
| Q2 25 | $181.1M | $172.6M | ||
| Q1 25 | $168.9M | $111.4M | ||
| Q4 24 | $187.3M | $87.3M | ||
| Q3 24 | $168.6M | $150.5M | ||
| Q2 24 | $178.0M | $160.1M |
净利润PCRXSWIM
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-7.0M | ||
| Q3 25 | $5.4M | $8.1M | ||
| Q2 25 | $-4.8M | $16.0M | ||
| Q1 25 | $4.8M | $-6.0M | ||
| Q4 24 | — | $-29.2M | ||
| Q3 24 | $-143.5M | $5.9M | ||
| Q2 24 | $18.9M | $13.3M |
毛利率PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 28.0% | ||
| Q3 25 | 80.9% | 35.4% | ||
| Q2 25 | 77.4% | 37.1% | ||
| Q1 25 | 79.7% | 29.5% | ||
| Q4 24 | 78.7% | 24.6% | ||
| Q3 24 | 76.9% | 32.4% | ||
| Q2 24 | 75.1% | 33.1% |
营业利润率PCRXSWIM
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -10.7% | ||
| Q3 25 | 3.5% | 13.3% | ||
| Q2 25 | 4.7% | 14.3% | ||
| Q1 25 | 1.2% | -4.4% | ||
| Q4 24 | 13.2% | -14.9% | ||
| Q3 24 | -82.8% | 8.9% | ||
| Q2 24 | 15.9% | 12.5% |
净利率PCRXSWIM
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -7.0% | ||
| Q3 25 | 3.0% | 5.0% | ||
| Q2 25 | -2.7% | 9.3% | ||
| Q1 25 | 2.8% | -5.4% | ||
| Q4 24 | — | -33.4% | ||
| Q3 24 | -85.1% | 3.9% | ||
| Q2 24 | 10.6% | 8.3% |
每股收益（稀释后）PCRXSWIM
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.06 | ||
| Q3 25 | $0.12 | $0.07 | ||
| Q2 25 | $-0.11 | $0.13 | ||
| Q1 25 | $0.10 | $-0.05 | ||
| Q4 24 | $0.38 | $-0.24 | ||
| Q3 24 | $-3.11 | $0.05 | ||
| Q2 24 | $0.39 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | — |
| 总债务越低越好 | — | $279.8M |
| 股东权益账面价值 | $653.9M | $405.9M |
| 总资产 | $1.2B | $823.2M |
| 负债/权益比越低杠杆越低 | — | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资PCRXSWIM
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
总债务PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $279.8M | ||
| Q3 25 | $376.7M | $281.1M | ||
| Q2 25 | $580.5M | $281.5M | ||
| Q1 25 | $583.4M | $306.9M | ||
| Q4 24 | $585.3M | $281.5M | ||
| Q3 24 | — | $282.8M | ||
| Q2 24 | — | $282.4M |
股东权益PCRXSWIM
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $405.9M | ||
| Q3 25 | $727.2M | $408.4M | ||
| Q2 25 | $757.8M | $398.4M | ||
| Q1 25 | $798.5M | $381.1M | ||
| Q4 24 | $778.3M | $387.2M | ||
| Q3 24 | $749.6M | $416.6M | ||
| Q2 24 | $879.3M | $408.1M |
总资产PCRXSWIM
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $823.2M | ||
| Q3 25 | $1.3B | $844.4M | ||
| Q2 25 | $1.5B | $822.1M | ||
| Q1 25 | $1.6B | $824.6M | ||
| Q4 24 | $1.6B | $794.2M | ||
| Q3 24 | $1.5B | $853.4M | ||
| Q2 24 | $1.6B | $830.0M |
负债/权益比PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.69× | ||
| Q3 25 | 0.52× | 0.69× | ||
| Q2 25 | 0.77× | 0.71× | ||
| Q1 25 | 0.73× | 0.81× | ||
| Q4 24 | 0.75× | 0.73× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $23.3M |
| 自由现金流经营现金流 - 资本支出 | — | $14.1M |
| 自由现金流率自由现金流/营收 | — | 14.1% |
| 资本支出强度资本支出/营收 | — | 9.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $38.0M |
8季度趋势，按日历期对齐
经营现金流PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $23.3M | ||
| Q3 25 | $60.8M | $51.0M | ||
| Q2 25 | $12.0M | $36.0M | ||
| Q1 25 | $35.5M | $-46.9M | ||
| Q4 24 | $33.1M | $6.2M | ||
| Q3 24 | $53.9M | $37.2M | ||
| Q2 24 | $53.2M | $52.4M |
自由现金流PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $14.1M | ||
| Q3 25 | $57.0M | $45.2M | ||
| Q2 25 | $9.3M | $29.1M | ||
| Q1 25 | $26.9M | $-50.3M | ||
| Q4 24 | $31.0M | $-98.0K | ||
| Q3 24 | $49.8M | $33.2M | ||
| Q2 24 | $51.6M | $47.9M |
自由现金流率PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 14.1% | ||
| Q3 25 | 31.7% | 27.9% | ||
| Q2 25 | 5.1% | 16.8% | ||
| Q1 25 | 15.9% | -45.2% | ||
| Q4 24 | 16.6% | -0.1% | ||
| Q3 24 | 29.6% | 22.1% | ||
| Q2 24 | 29.0% | 29.9% |
资本支出强度PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 9.2% | ||
| Q3 25 | 2.2% | 3.6% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 5.1% | 3.1% | ||
| Q4 24 | 1.1% | 7.2% | ||
| Q3 24 | 2.4% | 2.7% | ||
| Q2 24 | 0.9% | 2.8% |
现金转化率PCRXSWIM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 6.29× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.32× | ||
| Q2 24 | 2.82× | 3.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
